Bioceros is building a pipeline of early-phase promising proprietary therapeutic monoclonal antibodies, including targets in oncology and auto-immune disease. The company employs its validated technology platforms and pre-clinical development expertise to design and develop effective humanised monoclonal antibodies. To find out more please download this free white paper.